Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sanofi-Aventis S.A. (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 113,089,680
  • Shares Outstanding, K 2,508,088
  • Annual Sales, $ 42,135 M
  • Annual Income, $ 5,101 M
  • 60-Month Beta 0.53
  • Price/Sales 2.73
  • Price/Cash Flow 8.48
  • Price/Book 1.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.74
  • Number of Estimates 3
  • High Estimate 0.75
  • Low Estimate 0.72
  • Prior Year 0.79
  • Growth Rate Est. (year over year) -6.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.65 +10.92%
on 02/25/19
45.15 -0.13%
on 03/15/19
+2.54 (+5.97%)
since 02/15/19
3-Month
40.65 +10.92%
on 02/25/19
45.15 -0.13%
on 03/15/19
+1.04 (+2.36%)
since 12/14/18
52-Week
37.43 +20.46%
on 05/09/18
45.62 -1.16%
on 11/09/18
+4.54 (+11.20%)
since 03/15/18

Most Recent Stories

More News
Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study

Lexicon Pharma (LXRX) commences dosing of first patient in phase IIa study evaluating its marketed drug, Xermelo, in biliary tract cancer.

LXRX : 7.63 (+2.97%)
CELG : 88.38 (-0.09%)
KMDA : 6.14 (+0.66%)
SNY : 44.85 (-0.53%)
Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News

Key highlights of the past week are regulatory and pipeline developments.

CELG : 88.38 (-0.09%)
VRTX : 187.20 (-0.47%)
ZFGN : 3.01 (-0.66%)
AMAG : 12.57 (-0.79%)
REGN : 409.81 (-1.12%)
SNY : 44.85 (-0.53%)
Should Value Investors Consider Sanofi (SNY) Stock Now?

Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.

SNY : 44.85 (-0.53%)
Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion

The FDA approves a label expansion of Regeneron's (REGN) asthma drug, Dupixent for moderate-to-severe atopic dermatitis in adolescents.

BAYRY : 19.1000 (+0.16%)
CELG : 88.38 (-0.09%)
REGN : 409.81 (-1.12%)
SNY : 44.85 (-0.53%)
Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps

Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.

BAYRY : 19.1000 (+0.16%)
AZN : 42.55 (+0.09%)
REGN : 409.81 (-1.12%)
SNY : 44.85 (-0.53%)
Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA

The FDA accepts Roche's (RHHBY) sNDA for Xofluza to treat influenza in people at high risk of complications.

MRK : 81.65 (+0.10%)
RHHBY : 33.9300 (-0.82%)
GSK : 40.58 (-0.12%)
SNY : 44.85 (-0.53%)
Top Stock Reports for Salesforce, Booking Holdings & VMware

Top Stock Reports for Salesforce, Booking Holdings & VMware

VMW : 182.10 (+0.30%)
HPQ : 19.94 (-0.30%)
BKNG : 1,764.16 (+0.68%)
SNY : 44.85 (-0.53%)
MAR : 124.68 (+1.93%)
CRM : 162.29 (+0.48%)
Lilly to Bring Half-Priced Version of Popular Humalog Insulin

Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.

NVO : 51.35 (+0.90%)
LLY : 124.00 (+0.05%)
PFE : 41.88 (+0.24%)
SNY : 44.85 (-0.53%)
What's in the Cards for Novavax (NVAX) This Earnings Season?

Novavax (NVAX) is expected to provide updates on its lead vaccine candidate, Resvax when it reports fourth-quarter 2018 results.

BDSI : 4.95 (-0.60%)
TLRY : 72.89 (+0.54%)
NVAX : 0.52 (+1.96%)
SNY : 44.85 (-0.53%)
Regeneron-Sanofi Get CHMP Nod for Dupixent Label Expansion

The CHMP gives a positive opinion for the label expansion of Regeneron (REGN) and Sanofi's Dupixent for the treatment of asthma in Europe.

BAYRY : 19.1000 (+0.16%)
CELG : 88.38 (-0.09%)
REGN : 409.81 (-1.12%)
SNY : 44.85 (-0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade SNY with:

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Key Turning Points

2nd Resistance Point 45.49
1st Resistance Point 45.29
Last Price 44.85
1st Support Level 44.75
2nd Support Level 44.41

See More

52-Week High 45.62
Last Price 44.85
Fibonacci 61.8% 42.49
Fibonacci 50% 41.53
Fibonacci 38.2% 40.56
52-Week Low 37.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar